Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  liposome-encapsulated doxorubicin citrate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Drug-eluting Bead in Hepatocellular Carcinoma
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Other
Protocol IDs: Biocompatible-Korea, NCT01332669
Trial of Myocet in Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 an over
Sponsor: Pharmaceutical / Industry
Protocol IDs: STM01-102, NCT00294996
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22224, 2009-011400-33, NCT00976911
Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: MYCA (GINECO-OV220), 2012-001999-10, NCT01705158
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: C19562/2037, 2008-000709-12, NCT00712881
Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: GOG/2007-01, 2007-005173-56, NCT00721747
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX011-03, NCT01156753
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ABCSG 32, 2010-023324-25, NCT01367028
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: IIL - HD0803, EudraCT Number 2009-013839-37, NCT01523847
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 74
Sponsor: Other
Protocol IDs: SOLTI-1002, 2012-001201-24, NCT01669239
Start Over